The role of thrombophilia testing in 2025: An update for medical practice and points for consideration (notice n° 1572957)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01973cam a2200265 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251214025751.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Andrès, Emmanuel |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | The role of thrombophilia testing in 2025: An update for medical practice and points for consideration |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 17 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Thrombophilia testing aims to identify abnormalities that promote venous thrombosis, but its use is now limited. It is only recommended in specific cases: recurrent thrombosis, thrombosis at unusual sites, a family history of early-onset events, or suspected antiphospholipid syndrome. Testing includes the detection of genetic mutations (factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] mutations) and deficiencies in antithrombin, protein C, and protein S, as well as elevated homocysteine levels and acquired abnormalities such as antiphospholipid syndrome (APS). It may also include testing for myeloproliferative syndromes and paroxysmal nocturnal hemoglobinuria. However, its impact on patient management remains limited, as the presence of hereditary thrombophilia does not always alter the duration of anticoagulant treatment. Furthermore, the excessive use of these tests can lead to over-medicalization and significant costs without clear clinical benefit. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Terrade, Jean Edouard |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jannot, Xavier |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Habib, Charlène |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ghiura, Cosmina |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Taquet, Marie-Caroline |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Diallo, Alpha |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Nasco, Edward |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dalmas, Marie-Caroline |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lorenzo-Villalba, Noël |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Cahiers Santé Médecine Thérapeutique | 34 | 4 | 2025-10-01 | p. 273-278 | 2780-8858 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-cahiers-sante-medecine-therapeutique-2025-4-page-273?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-cahiers-sante-medecine-therapeutique-2025-4-page-273?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux